CN1187086C - 具有经非免疫原性肽连接在一起的干扰素α和免疫球蛋白Fc的杂合体 - Google Patents
具有经非免疫原性肽连接在一起的干扰素α和免疫球蛋白Fc的杂合体 Download PDFInfo
- Publication number
- CN1187086C CN1187086C CNB961994223A CN96199422A CN1187086C CN 1187086 C CN1187086 C CN 1187086C CN B961994223 A CNB961994223 A CN B961994223A CN 96199422 A CN96199422 A CN 96199422A CN 1187086 C CN1187086 C CN 1187086C
- Authority
- CN
- China
- Prior art keywords
- ifn
- gly
- ser
- heterozygote
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 20
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 11
- 102000018358 immunoglobulin Human genes 0.000 title claims description 11
- 230000002163 immunogen Effects 0.000 title description 3
- 108010050904 Interferons Proteins 0.000 claims abstract description 19
- 102000014150 Interferons Human genes 0.000 claims abstract description 19
- 229940079322 interferon Drugs 0.000 claims abstract description 18
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 claims abstract description 12
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims abstract description 9
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims abstract description 8
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 3
- 239000000710 homodimer Substances 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 8
- 108010047761 Interferon-alpha Proteins 0.000 abstract description 4
- 102000006992 Interferon-alpha Human genes 0.000 abstract description 4
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 abstract 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000008521 reorganization Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 102220023256 rs387907547 Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 102220369445 c.668T>C Human genes 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 231100000146 endocrine toxicity Toxicity 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000010376 human cloning Methods 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 102000014650 luteinizing hormone receptor activity proteins Human genes 0.000 description 1
- 108040006978 luteinizing hormone receptor activity proteins Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 102220023257 rs387907546 Human genes 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明涉及一种杂合的重组蛋白,其含有人类干扰素,优选是干扰素-α(IFNα),及人类免疫球蛋白Fc片段,优选是γ4链,经由肽接头连接,肽接头序列为Gly Gly Ser Gly Gly Ser Gly Gly GlyGly Ser Gly Gly Gly Gly Ser(SEQ ID NO:1)。
Description
发明背景
干扰素-α(“IFNα”)是以重组DNA技术所产生的第一种细胞因子,且已示出在如发炎,病毒及恶性疾病等状况下具有治疗价值。许多种IFNα制剂,包括纯化自天然来源及由重组DNA技术所产生者已被应用,且于各种恶性及病毒疾病中被测试。IFNα可造成某些已发展肿瘤的消退,且在某些病毒感染中诱导阴性反应。目前为止,IFNα已于许多国家中被许可或试验于以下适应症:如卡波西氏肉瘤;多毛细胞白血病;恶性黑色素瘤;基础细胞癌;多发性骨髓瘤;肾细胞癌;B型肝炎;C型肝炎;花柳疣;I/II疱疹,水痘/输状疱疹及蕈样肉芽肿。
大多数的细胞因子,包括IFNα,由于于活体内产生以局部及暂时作用,因此有相当短的循环半衰期。IFNα的血清半衰期仅约2至8小时(Roche Labs.Refferon A,Schering Intron A,Physicians’DeskReference,47th edition,1993,pp.2006-2008,2194-2201)。为运用IFNα作为有效的全身性治疗剂,其需以极大剂量且经常给药。例如,对AIDS-相关的卡波西氏肉瘤的建议疗程之一是始自每天3千6百万IU的诱导剂量历10至12周,以肌内或皮下注射方式给予,继以3千6百万IU的维持剂量,一周3次。(Roche Labs.Referon a,Physicians’Desk Reference,47th edition,1993,pp.2006-2008)。此种经常性肠外给药是不方便且令人疼痛的。再者可能由高剂量引起的毒性作用,为某些患者的难处所在。据报道有皮肤,神经学,内分泌及免疫毒性。为克服这些缺点,可修饰分子以增加其循环半衰期或改变药物的配方以延长其释出时间。剂量及给药频率可减少而仍增加其效力。据报,低于9百万单位的剂量,是可耐受的,而高于3千6百万单位的剂量常会诱生严重的毒性及显著地改变病人状况。(Quesada,J.R.et al.,J.Clin,Oncol.,4:234-43,1986)。经由产生新的IFNα也可能实质地减少毒性作用,该新的IFNα可在循环中更稳定且需更少剂量。目前已致力于制造滞留时间有所延长的重组IFNα-明胶缀合物(Tabata,Y.et al.,Cancer Res.51:5532-8,1991)。于动物中也已试验以脂质为基础的胶囊化IFNα配制物,并达到蛋白质在腹膜中延长的释放(Bonetti,A.and Kim,S.Cancer ChemotherPharmacol.33:258-261,1993)。
IgG及IgM类免疫球蛋白为人体血液中含量最丰富的一类。其循环半衰期由数天至21天。当用于形成重组杂合体时,发现IgG可增加许多配体结合蛋白质(受体)的半衰期,包括可溶性CD4分子,LHR及IFN-γ受体(Mordenti J.et al.,Nature,337:525-31,1989;Capon,D.J.and Lasky,L.A.,美国专利5,116,964;Kurschner,C.et al.,J.Immunol.149:4096-4100,1992)。然而,此种杂合体出现难题,即在活性部份C-末端的肽,及在Fc部分N-末端的肽,在融合处会生成新的肽序列,其是一种新抗原,且具免疫原性。本发明涉及一种IFNα-Fc杂合体,其经过设计可克服此问题并延长IFNα的半衰期。
发明概述
本发明涉及由二个亚基组成的杂合体重组蛋白质。每个亚基包括一个人类干扰素,较好是IFNα,由一个肽接头连接,其主要由T细胞惰性序列所组成,连接至人类免疫球蛋白Fc片段上,较好是γ4链。γ4链优于γ1,因为前者的补体活化能力较少或无此能力。本发明还涉及该杂合体分子在制备用于治疗肝炎、多毛细胞白血病、多发性骨髓瘤或其它癌症或病毒疾病的药物中的应用。
IFNα的C-末端连接至Fc片段的N-末端。额外的IFNα(或其他细胞因子)可粘附至Fc片段其他任何未结合Fc链的N-末端上,产生γ4链的同二聚体。若所选择的Fc片段是另一链,如μ链,则由于Fc片段可与10个可能的结合位点形成五聚体,此可生成有干扰素或其他细胞因子在10个结合位点中的每一个上连接的分子。
杂合体的二个部分经由T细胞免疫学上惰性的肽而连接,如GlyGly Ser Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser(SEQ IDNO:1)。此肽本身是免疫学上无活性的。在融合点处将此肽插入,可将由于二个肽部分连接所产生的新抗原性消除。接头肽也可增加这些部分的挠性,且可保留生物活性。此相对较长的接头肽有助于克服由杂合体Fc部分来的可能的立体位阻,后者可干扰杂合体的活性。
杂合体有较天然IFNα延长的半衰期。由于接头,也可设计以将产生新的免疫原性表位(新抗原)的可能性减低,此点是IFNα及免疫球蛋白Fc片段的融合点。
细胞因子通常是有相当短半衰期的小蛋白质,其可在各种组织中,包括不希望位置,快速消失。据信少量的某些细胞因子可穿越血脑障壁,并进入中枢神经系,由是造成严重的神经毒性。IFNα连接至本发明的Fcγ,将尤其可适用于治疗B或C型肝炎,因为这些产物在血管内(一旦经静脉内给药)有长的滞留时间,且不会穿透不希望的位置。
本文所述的特异杂合体也可充作设计及构建其他细胞因子-Fc杂合体的模型。可使用相同或类似的接头以减少产生新的免疫原性表位的可能性,同时保留生物活性。利用相同的技术可制成其中白介素-2是细胞因子的细胞因子-Fc杂合体,或包括有其他细胞因子的杂合体。
发明详述
本发明的杂合体分子包括一个干扰素部分,经由独特的接头连接至免疫球蛋白Fc部分。优选地,二个干扰素部分的C-末端分别地粘附至重链γ4Fc片段的二个N-末端上,而生成一个同二聚体结构。可生成独特的接头肽,Gly Gly Ser Gly Gly Ser Gly Gly Gly GlySer Gly Gly Gly Gly Ser(SEQ ID NO:1),以连接二部分。较佳的γ4杂合体的完整核苷酸序列(包括接头及Fc部分)示于SEQ IDNO:7中,且接头位于189至204号氨基酸残基。
杂合体甚于天然细胞因子的优点在于活体内的半衰期更长。包括干扰素及γ4链Fc同二聚体的杂合体较天然干扰素还大。由于肝中血管的孔径较大,此大分子更适用于治疗肝炎,在此病毒主要是负责侵蚀肝脏。
接头肽经过设计可增加二部分的挠性,且因此维持其生物活性。虽然干扰素及免疫球蛋白均源自人体,在二分子融合点处始终有产生新的免疫原性表位的可能性。因此,本发明接头(其主要由T细胞惰性序列所组成)的其他优点在于可在融合点减低免疫原性。于SEQ ID NO:7中可见,若接头(189-204号残基)不存在,可生成由第189号前的残基及204号后的残基所组成的新序列。此新序列对人体而言将是一个新抗原。
人类IFNα衍生自许多不同基因的一个家族。自基因及蛋白质序列资料中,目前已鉴定出24种以上。其到处有相异处,从几个至最多35个氨基酸不同。大多数有一个23个氨基酸残基的信号肽序列,及166个氨基酸残基的成熟氨基酸序列(Goeddel,D.V.et al.,Nature,290:20-261981:Weissmann,C.and Weber,H.,Prog.Nuc.AcidRes.Mol.Biol.33;251-300,1986;Zoon,K.C.,Interferon,9:1-12,1987)。
IFNα2(也称为IFNαA)为最被充分研究的干扰素之一。IFNα2的重组体型式已充作治疗剂使用达数年。目前买得到的二种IFNα重组体产物为IFNα2a及IFNα2b,其相异处仅在第23位的一个氨基酸,且二者生物活性间并无显著不同(von Gabain,A.,et al.,Eur.J.Biochem.190:257-61,1990)。
IFNα2a被选为本发明干扰素杂合体的融合配对物,当然IFNα2b或其他的干扰素(包括IFNβ)也可使用。以其他细胞因子也可制备类似的构建体,如白介素-1或白介素-2。可使用相同的连接,不具有免疫原性且可保有构建体生物活性者也可替代的。
杂合体中以γ4链作为Fc部分的优点在于其在人循环中是稳定的。γ4(和γ1链不同)可避免广谱的二级生物特性,如补体固定及抗体依赖性细胞介导的胞毒性(ADCC),这些可能是不希望的特性。
IFNα2a的cDNA可由反转录作用及PCR获得,利用从表达IFNα的白细胞提取的RNA而进行。此种细胞株之一,KG-1可得自美国典型培养物保藏中心(ATCC),Rockville,Maryland,其编号为CCL 246。在制备本发明杂合体的步骤中,于RNA提取的前,细胞以仙台病毒攻击以增加干扰素的转录作用(Cantell,K.et al.,Methodsin Enzymology,78A:29-38,Adacemic Press,1981)。
如上所述,IFNα为IFN的集合,且每一细胞可在相同时间表达许多不同的IFNα亚型。在这些各型DNA序列的同源性如此高以致RT-PCR可能扩增一群而非特殊的一种。为特异地获得IFNα2acDNA,要设计PCR引物,如此二个引物的最后一个核苷酸可在IFNα2a独有的氨基酸密码处结束。其分别是位置S22和161(见Zoon,K.C.Interferon,9:1-12,1987)。
利用重叠的PCR技术(Daugherty,B.L.et al.,Nucleic Acids Res,19:2471-6,1991),可在所希望的任何位置处容易地连接二个基因片段。然而,PCR扩增作用的一个缺点是相当高的突变比例(Saiki,R.K.et al.,Science,239:487,1988)。因此也进行DNA测序以检查由PCR获得的每一个DNA片段有否突变。当片段大小超过1kb时,测序是冗长且费时的,全长的IFNα-Fc cDNA也是如此。然而,可将限制酶BamHI位点引入接头核苷酸序列中,而不改变其氨基酸序列。此位点位于SEQ ID NO:1的核苷酸15及16之间。
来自PCR的二个基因片段可分别克隆至克隆载体内。此使DNA更易且更快被测序,因为二片段仅数百碱基对长。一旦鉴定出有正确DNA序列的克隆,二个基因片段可经由BamHI位置连接在一起。不需第二轮的重叠PCR及接下来全长片段的DNA测序工作。
体外表达重组蛋白质的方式有许多种,包括于大肠杆菌,杆状病毒,酵母,哺乳动物细胞或其他表达系统。原核细胞系统大肠杆菌无法进行转译后修饰作用,如糖基化作用。但此点对IFNα-Fc杂合体而言并非严重问题,因为天然的IFNα及免疫球蛋白γ4分子并未严重糖基化。再者已有报告指出,无任何糖基化作用的重组IFNα可保有其生物学活性(Baron,E.and Narula,S.,Bio/technology,10:179-190,1990)。然而,自大肠杆菌溶胞产物中纯化重组蛋白质是十分困难的。由大肠杆菌表达的外来蛋白质常会聚集且形成不溶的包涵体。因此常需要包涵体的溶解作用及接下来的再折叠(Schein,C.H.and Noteborn,H.M.,Bio/technology,6:291-294,1988;Wilkinson,D.L.and Harrison,R.G.,Bio/technology,9:443-448,1991)。
酵母表达系统巴斯德毕赤酵母(Invitrogen,San Diego,CA)可克服利用细菌系统时所遇到的某些问题,其通常可生成高产率,且有能力进行各种转译后处理修饰作用。所表达的外来蛋白质可分泌至培养物上清液中,其中并无其他许多蛋白质存留,而使得蛋白质的纯化作用及过程的扩大更为容易。此系统先可表达IFNα-Fc杂合体或野生型IFNα2a。不幸地,IFNα-Fc分泌出后发现在SDS-PAGE上会部分降解,而单独的IFNα2a则否。据信降解作用是由酵母表达系统中存在的蛋白酶活性所致,此由Scorer,C.A.et.Al.,Gene,136:111-9,1993中所报告。在枢钮区中相当弱的点可能是蛋白酶的靶。
也尝试IFNα-Fc杂合体的哺乳动物细胞表达系统。采用了哺乳动物表达载体,pCDNA3(Invitrogen,San Diego,CA),其含有一个CMV启动子及一个NEO抗性基因。宿主细胞,NSO细胞,以pCDNA3/IFNα-Fc表达载体利用电穿孔法转染。细胞以0.8毫克/毫升浓度的G418选择。以ELISA鉴定表达IFNα-Fc的克隆。于此系统杂合体可成功地表达,且无降解现象。
在此哺乳动物表达系统中有许多优点。首先,重组蛋白质分泌至培养物上清液中,且在此无聚集作用,由是可简化纯化作用。利用蛋白质A管柱的一个层析步骤可得到经纯化的IFNα-Fc蛋白质。同时以此系统产生的蛋白质,其糖基化作用型式和天然分子极相似,因其以哺乳动物细胞表达。再者,天然的IFNα2a信号肽序列包括于表达载体中。因此由细胞分泌的蛋白质具有真实的N-末端,然而,在大肠杆菌或酵母表达系统中,或是无信号肽或是使用非IFNα信号肽。不论何者,可在重组IFNα-Fc的N-末端带来额外的人工氨基酸残基。
如上所述,自培养物上清液中纯化IFN-αFc重组蛋白质是相当直接的。经由蛋白质A管柱的单步骤亲和层析,可容易地获得纯度在90%以上的蛋白质(经SDS-PAGE判断)。
检测IFNα生物活性有许多分析方法可应用。利用抗病毒分析法,已证明SEQ ID NO:7的杂合体,具有约5至10倍高于相关IFNα-Fc杂合体的比活性,其中接头分子具有Gly Gly Ser Gly Gly Ser序列(SEQ ID NO:2),且杂合体的Fc部分衍生自人类IgG1而非IgG4。然而,虽然示于SEQ ID NO:7中的杂合体的生物活性有实质地改进,其仍较天然IFNα为低。然而可预期,此杂合体有更长的体内半衰期。此期望以下列证明结果为基础,即在一个小鼠模型中,具有Gly Gly Ser Gly Gly Ser接头序列及IgGl Fc部分的相关IFNα杂合体有较天然IFNα更长的半衰期。
因为SEQ ID NO:7的杂合体预期有较天然IFNα更长的体内半衰期,因此即便其比活性较低,就临床应用而言,此新的杂合体应优于天然的IFNα。这是因为较长的半衰期结果,使Cxt(浓度对时间曲线下的面积)可数百倍大于天然IFNα。此意味在天然IFNα及杂合体相同摩尔浓度剂量下,后者可提供数百倍增加的IFNα的曝露程度,造成在相同剂量下极为增加的效力,且给药频率可较低。
在检测比活性时,摩尔浓度较佳可替代按每蛋白质质量下的单位计的表达活性。此乃因为干扰素经由与其特异受体结合而作用,此和存在的分子数目直接有关。同时,IFNα-Fcγ4的分子量(110Kd)约5倍多于野生型IFNα2a(20Kd)。考量此点,按单位/微摩尔计的检测活性替代按单位/毫克计,可提供活性特异性更佳的比较。
实施例1克隆人IFNαcDNA及构建IFNα-Fc表达载体
6×106个KG-1细胞(ATCC 246)与200单位的仙台病毒在37℃下培育一夜。回收细胞,再以PBS充分洗涤。利用RNA-ZOL RNA分离试剂盒(BIOTEX,Houston,TX)依循厂商的操作指示提取总RNA。以逆转录作用,利用AMV反转录酶,并以寡(dT)为3’引物,于50mM Tris-HCl(pH 8.3)、60mMKCl及6mM MgCl2中,以42℃培育1小时合成第一链cDNA。反应混合物直接用作PCR的模板以扩增IFNα cDNA。用于PCR的5’引物含有一个Hind III位点,及来自IFNα 2a前导肽前21个氨基酸的编码序列(SEQ ID NO:3)。3’引物含有编码部分接头(SEQ ID NO:1)及IFNα 2a后5个氨基酸,且整合在接头序列中的一个BamHI位点的序列(SEQ IDNO:4)。PCR缓冲溶液含有50mM KCl,10mMTris-Hcl(pH8.3),1.5mMMgCl2,0.01%明胶,0.1毫摩尔每种dNTP,0.5微摩尔每种引物,5微升RT反应混合物,及1单位Taq DNA聚合酶,于共50微升体积中。PCR条件为94℃(1分钟),55℃(2分钟)及72℃(2分钟),40个循环于GeneAmp PCR系统9600(Perkin Elmer,Norwalk,CT)。
以逆转录作用及PCR得到人类免疫球蛋白γ4Fc的cDNA,如上述方式进行。RNA提取自人类扁桃腺B细胞。5’引物具有SEQ IDNO:5所示序列。3’引物具有SEQ ID NO:6所示序列。
二个PCR扩增的DNA片段克隆至pUC18中,分别在HindIII/BamI位点或BamHI/EcoRI位点。其DNA序列以来自USB(Cleveland,Ohio)的DNA测序用试剂盒证实后,二个片段经由BamH I位点以第二轮克隆连接在一起。全长的IFNα-Fc cDNA再嵌入哺乳动物表达载体pCDNA3内(Invitrogen,San Diego,CA),经由HindIII及EcoRI位点插入。
实施例2:IFNα-Fc于哺乳动物细胞中的表达
将107个NSO细胞与10微克线化的pcDNA3/IFNα-Fc质粒混合于0.8毫升PBS中,并置冰中5分钟。在200v,960μF下利用GenePulser(BioRad,Hircules,CA)进行电穿孔。细胞再置回冰上20分钟,并转移至加有10毫升DMEM(并添加2%FCS)的100毫米组织培养皿内。经在37℃下培育2天后,洗涤细胞并再悬浮于相同培养基中。加入0.6毫克/毫升G418开始筛选。细胞涂布在8个96孔微板上,并在37℃下培育。一周后出现集落,其可在2周内容易地筛选。各孔的上清液,若有单一集落生长者则予以收集。在上清液中的IFNα-Fc经ELISA分析法定量决定,此中应用与辣根过氧化物酶缀合的山羊抗人类IgG及抗人Fc。选出具较高ELISA读值及较小集落尺寸的克隆进一步亚克隆。这些集落转移至24孔板内,并供应以含有G418的培养基。将具最高分泌水平的克隆扩大,并使其在旋转器中生长。于大规模制备时,收集培养物上清液,并通过以PBS平衡的蛋白质A琼脂糖柱。结合至蛋白质A的蛋白质以50mM柠檬酸盐(pH3.0)洗脱,并以冷冻干燥法浓缩。
实施例3:鉴定IFNα-Fc杂合体
分离自NSO培养基的重组蛋白质,其纯度以SDS-PAGE及Western印迹法检查。在针对所有蛋白质以丽春红S染色的吸印迹膜上可见仅一条蛋白质带,显示蛋白质制剂的同质性。此蛋白质的表观分子量在还原条件下为约55kd,在非还原条件下为110kd,此确实是IFNα-Fc杂合体的预期大小。在非还原条件下,其表观分子量的加倍提示了此杂合体呈二聚体型式。重组蛋白质可由抗-Fc及抗-IFNα抗体所确认,证实其由二个部份,IFNα及Fc片段所组成。
对IFNα-Fc的生物活性分析是一种抗病毒分析法。特言的,所使用的分析方法为Rodert M.Friedman et al所述策略的修饰(Measurement of antiviral activity induced by interferons α,βandγ,Current Protocols in Immunology,1994,pp.6.9.1-6.9.8)。简言的,人类肺癌细胞(A549,ATCC#CCL185)以40,000细胞/孔的密度种入96孔板内,并在37℃下培育24小时。加入1∶2系列稀释的IFNα-Fc杂合体或天然的IFNα(NIH#GXA01-901-535),并在37℃下培育24小时。每一样品进行三次。培养基以含有浓度约0.1MOI/细胞的脑心肌炎病毒(ATCC#VR 129B)的新鲜培养基替换,并在37℃下再培养48小时。死细胞吸出洗去,并以PBS充分洗涤。已粘附的细胞以2%甲醛固定,再以吉姆萨染料染色。板以自来水润洗再令其干燥。经染色的细胞以甲醇溶解,样品在595毫微米下分光光度地读取。IFNα-Fc杂合体的抗病毒活性与IFNα标准品比较而评估,且发现是IFNα标准品活性的约30-60%。
应了解,此中所使用的术语及表示仅供示范但不予以限制,且本发明范围仅由其后的权利要求书所定义,并包括这些权利要求主题中的所有同等事件。
序列表
(1)一般信息:
(i)申请人:Yu Liming;Chang,Tse Wen
(ii)发明名称:具有经非免疫原性肽连接在一起的干扰素α和免疫球蛋白Fc的杂合体
(iii)序列数:7
(iv)通信地址:
(A)收信人:泰诺克斯生物系统公司
(B)街道:10301 Stella Link Rd.
(C)城市:休斯敦
(D)州:德克萨斯州
(E)国家:美国
(F)邮编:71025
(v)计算机可读形式
(A)媒介类型:3.5英寸软盘
(B)计算机:Addonics C142 SVGA
(C)操作系统:DOS 3.30
(D)软件:Wordpeffect
(vi)本申请资料
(A)申请号:
(B)申请日:
(C)分类:
(vii)在先申请资料
(A)申请号:08/579,211
(B)申请日:1995.12.28
(viii)律师/代理人信息:
(A)姓名:Mirabel,Eric D.
(B)注册号:31,211
(C)卷号/文档号:95-2-PCT
(ix)电迅信息:
(A)电话:(713)664-2288
(B)传真:(713)664-8914
(2)SEQ ID NO:1的信息
(i)序列特征
(A)长度:48个核苷酸
(B)类型:核苷酸
(C)链性:双链
(D)拓扑学:线性
(xi)序列描述:SEQ ID NO:1
GGT GGC TCA GGT GGA TCC GGT GGA GGC GGA AGC GGC 35
Gly Gly Ser Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10
GGT GGA GGA TCG 48
Gly Gly Gly Ser
15
(2)SEQ ID NO:2的信息
(i)序列特征
(A)长度:6个氨基酸
(B)类型:氨基酸
(D)拓扑学:未知
(xi)序列描述:SEQ ID NO:2
Gly Gly Ser Gly Gly Ser
1 5
(2)SEQ ID NO:3的信息
(i)序列特征
(A)长度:81个核苷酸
(B)类型:核苷酸
(C)链性:单链
(D)拓扑学:线性
(xi)序列描述:SEQ ID NO:3
CATAAGCTTC ATCTACAAT GGCCTCACCT TTGCTTTACT 40
GGTGGCCCTC CTGGTGCTCA GCTGCAGTC AAGCTGCTCT G 81
(2)SEQ ID NO:4的信息
(i)序列特征
(A)长度:40个核苷酸
(B)类型:核苷酸
(C)链性:单链
(D)拓扑学:线性
(xi)序列描述:SEQ ID NO:4
CTCTGCGGAT CCACCTGAGC CACCTTCCTT ACTTCTAAA 40
(2)SEQ ID NO:5的信息
(i)序列特征
(A)长度:58个核苷酸
(B)类型:核苷酸
(C)链性:单链
(D)拓扑学:线性
(xi)序列描述:SEQ ID NO:5
AATGGATCCG GTGGAGGCG AAGCGGCGGT GGAGGATCAG 40
AGTCCAAATA TGTCCCC 58
(2)SEQ ID NO:6的信息
(i)序列特征
(A)长度:42个核苷酸
(B)类型:核苷酸
(C)链性:双链
(D)拓扑学:线性
(xi)序列描述:SEQ ID NO:6
ATCGAATTCT ATTTACCCAG AGACAGGGAG AGGCTCTTCT GT 42
(2)SEQ ID NO:7的信息
(i)序列特征
(A)长度:1302个核苷酸
(B)类型:核苷酸
(C)链性:双链
(D)拓扑学:线性
(xi)序列描述:SEQ ID NO:7
ATG GCC TTG ACC TTT GCT TTA CTG GTG GCC CTC CTG GTG 39
Met Ala Leu Thr Phe Ala Leu Leu Val Ala Leu Leu Val
1 5 10
CTC AGC TGC AAG TCA AGC TGC TCT CTG GGC TGT GAT CTG 78
Leu Ser Cya Lys Ser Ser Cys Ser Leu Gly Cys Asp Leu
15 20 25
CCT CAA ACC CAC AGC CTG GGT AGC AGG AGG ACC TTG ATG 117
Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
30 35
CTC CTG GCA CAG ATG AGG AAA ATC TCT CTT TTC TCC TGC 156
Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cya
40 45 50
TTG AAG GAC AGA CAT GAC TTT GGA TTT CCC CVG GAG GAG 195
Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu
55 60 65
TTT GGC AAC CAG TTC CAA AAG GCT GAA ACC ATC CCT GTC 234
Phe Gly Asn Gln Phe Gln Lys Ala Glu Thr Ile Phe Val
70 75
CTG CAT GAG ATG ATC CAG CAG ATC TTC AAT CTC TTC AGC 273
Leu His Glu Met Ile Glu Glu Ile Phe Asn Leu Phe Ser
80 85 90
ACA AAG GAC TCA TCT GCT GCT TGG GAT GAG ACC CTC CTA 312
Thr Lya Asp Ser Ser Ala Ala Trp Asp Gln Thr Leu Leu
95 100
GAC AAA TTC TAC ACT GAA CTC TAC CAG CAG CTG AAT GAC 351
Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp
105 110 115
CTG GAA GCC TGT GTG ATA CAG GGG GTG GGG GTG ACA GAG 390
Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu
120 125 130
ACT CCC CTG ATG AAG GAG GAC TCC ATT CTG GCT GTG AGG 429
Thr Pro Leu Met Lys Glu Asp Ser Ile Leu Ala Val Arg
135 140
AAA TAC TTC CAA AGA ATC ACT CTC TAT CTG AAA GAG AAG 468
Lys Tyr Phe Gln Arg Ile Thr Leu Tyr Leu Lys Glu Lys
145 150 155
AAA TAC AGC CCT TGT GCC TGG GAG GTT GTC AGA GCA GAA 507
Lys Tyr Ser Phe Cys Ala Trp Glu Val Val Arg Ala Glu
160 165
ATC ATG AGA TCT TTT TCT TTG TCA ACA AAC TTG CAA GAA 546
Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu
170 175 180
AGT TTA AGA AGT AAG GAA GGT GGC TCA GGT GGA TCC GGT 585
Ser Leu Arg Ser Lys Glu Gly Gly Ser Gly Gly Ser Gly
185 190 195
GGA GGC GGA AGC GGC GGT GGA GGA TCA GAG TCC AAA TAT 624
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ser Lys Tyr
200 205
GGT CCC CCG TGC CCA TCA TGC CCA GCA CCT GAG TTC GTG 663
Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu
210 215 220
GGG GGA CCA TCA GTC TTC CTG TTC CCC CCA AAA CCC AAG 702
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
225 230
GAC ACT CTC ATG ATC TCC CGG ACC CCT GAG GTC ACG TGC 741
Asp Thr Leu Met Ile Sar Arg Thr Pro Glu Val Thr Cys
235 240 245
GTG GTG GTG GAC GTG AGC CAG GAA GAC CCC GAG GTC CAG 780
Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln
250 255 260
TTC AAC TGG TAC GTG GAT GGC GTG GAG GTG CAT AAT GCC 819
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
265 270
AAG ACA AAG CCG CGG GAG GAG CAG TTC AAC AGC ACG TAC 858
Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr
275 280 265
CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG 897
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Typ
290 295
CTG AAC GGC AAG GAG TAC AAG TGC AAG GTC TCC AAC AAA 936
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
300 305 310
GGC CTC CCG TCC TCC ATC GAG AAA ACC ATC TCC AAA GCC 975
Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
315 320 325
AAA GGG CAG CCC CGA GAG CCA CAG GTG TAC ACC CTG CCC 1014
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
330 335
CCA TCC CAG GAG GAG ATG ACC AAG AAC CAG GTC AGC CTG 1053
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
340 345 350
ACC TGC CTG GTC AAA GGC TTC TAC CCC AGC GAC ATC GCC 1092
Thr Cya Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
355 360
GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC 1131
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asp Tyr
365 370 375
AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC GGC TCC TTC 1170
Lys Thr Thr Pro Pro Val Leu Asp Ser Aep Gly Ser Phe
380 385 390
TTC CTC TAC AGC AGG CTA ACC GTG GAC AAG AGC AGG TGG 1209
Phe Lys Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp
395 400
CAG GAG GGG AAT GTC TTC TCA TGC TCC GTG ATG CAT GAG 1248
Gln Gln Gly Asn Val Phe Ser Cye Ser Val Met His Glu
405 410 415
GCT CTG CAC AAC CAC TAC ACA CAG AAG AGC CTC TCC CTG 1287
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
420 425
TCT CTG GGT AAA TAG 1302
Ser Leu Gly Lys
430
Claims (5)
1、一种呈单体形式的杂合体分子,由在C-末端经由一个肽接头连接至免疫球蛋白Fc片段的N-末端的一个干扰素分子组成,所述肽接头由序列Gly Gly Ser Gly Gly Ser Gly Gly Gly Gly Ser Gly GlyGly Gly Ser组成。
2、一种呈同二聚体形式的杂合体分子,其由两个亚单位组成,每个亚单位包括在C-末端经由一个肽接头连接至免疫球蛋白Fc片段的N-末端的一个干扰素分子,所述肽接头由序列Gly Gly Ser GlyGly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser组成。
3、根据权利要求2的杂合体分子,其中干扰素分子是IFNα2a或IFNα2b。
4、根据权利要求2的杂合体分子,其中Fc片段是γ4链Fc片段。
5、权利要求1-4任一项的杂合体分子在制备用于治疗肝炎、多毛细胞白血病、多发性骨髓瘤或其它癌症或病毒疾病的药物中的应用。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57921195A | 1995-12-28 | 1995-12-28 | |
US08/579,211 | 1995-12-28 | ||
US08/719,331 US5723125A (en) | 1995-12-28 | 1996-09-25 | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US08/719,331 | 1996-09-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1206350A CN1206350A (zh) | 1999-01-27 |
CN1187086C true CN1187086C (zh) | 2005-02-02 |
Family
ID=27077703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB961994223A Expired - Fee Related CN1187086C (zh) | 1995-12-28 | 1996-12-13 | 具有经非免疫原性肽连接在一起的干扰素α和免疫球蛋白Fc的杂合体 |
Country Status (12)
Country | Link |
---|---|
US (2) | US5723125A (zh) |
EP (1) | EP0888122B1 (zh) |
JP (1) | JP3507507B2 (zh) |
CN (1) | CN1187086C (zh) |
AT (1) | ATE355074T1 (zh) |
AU (1) | AU701579B2 (zh) |
CA (1) | CA2239522A1 (zh) |
DE (1) | DE69636938T2 (zh) |
HK (1) | HK1017261A1 (zh) |
ID (1) | ID16083A (zh) |
MY (1) | MY116588A (zh) |
WO (1) | WO1997024137A1 (zh) |
Families Citing this family (196)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
US20030026779A1 (en) * | 1999-10-15 | 2003-02-06 | Liming Yu | Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc |
US6114110A (en) * | 1996-01-16 | 2000-09-05 | University Of Michigan | Isolation and propagation of a human herpesvirus derived from AIDS-associated Kaposi's sarcoma cells |
US20050033033A1 (en) * | 1998-05-04 | 2005-02-10 | Heinz Kohler | Trans-membrane-antibody induced inhibition of apoptosis |
US20030103984A1 (en) * | 1998-05-04 | 2003-06-05 | Heinz Kohler | Fusion proteins of biologically active peptides and antibodies |
US20040185039A1 (en) * | 2002-08-30 | 2004-09-23 | Heinz Kohler | Therapeutic applications of noncovalent dimerizing antibodies |
US7569674B2 (en) * | 1998-05-04 | 2009-08-04 | Innexus Biotechnology International Limited | Autophilic antibodies |
AU763719B2 (en) | 1997-12-08 | 2003-07-31 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
EP1042459A4 (en) * | 1997-12-24 | 2003-07-23 | Diatech Pty Ltd | BIFUNCTIONAL MOLECULES |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
CA2328076C (en) * | 1998-04-15 | 2009-10-06 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
US20090208418A1 (en) * | 2005-04-29 | 2009-08-20 | Innexus Biotechnology Internaltional Ltd. | Superantibody synthesis and use in detection, prevention and treatment of disease |
SI1121382T1 (sl) * | 1998-10-16 | 2007-02-28 | Biogen Idec Inc | Fuzijski proteini interferona-beta in uporabe |
CN100480266C (zh) * | 1998-10-16 | 2009-04-22 | 拜奥根Idec马萨诸塞公司 | 干扰素-β融合蛋白及用途 |
LT2599503T (lt) * | 1998-10-16 | 2017-06-26 | Biogen Ma Inc. | Interferono beta-1a polimero konjugatai ir jų panaudojimas |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6913749B2 (en) * | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
CZ20014123A3 (cs) * | 1999-05-19 | 2002-06-12 | Lexigen Pharmaceuticals Corp. | Exprese a export interferonů-alfa jako Fc fúzních proteinů |
EP1860188B1 (en) | 1999-07-07 | 2011-05-04 | ZymoGenetics, Inc. | Human cytokine receptor |
CA2379388C (en) * | 1999-07-13 | 2012-05-29 | George N. Cox, Iii | Immunoglobulin fusion proteins |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
CA2380331C (en) * | 1999-08-09 | 2012-11-20 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
ATE355368T1 (de) * | 2000-01-24 | 2006-03-15 | Gendaq Ltd | Nucleinsäure bindende polypeptide gekennzeichnet durch flexible linker verbundene nucleinsäuredomäne |
CA2399832C (en) * | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
AU2001271729B2 (en) * | 2000-06-29 | 2007-01-04 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
US20020169290A1 (en) * | 2000-11-02 | 2002-11-14 | Claus Bornaes | New multimeric interferon beta polypeptides |
EP1334128A2 (en) * | 2000-11-02 | 2003-08-13 | Maxygen Aps | New multimeric interferon beta polypeptides |
EP1507870A4 (en) * | 2000-12-01 | 2005-11-09 | Diversa Corp | ENZYMS WITH DEHALOGENASE ACTIVITY AND METHOD FOR THEIR USE |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US7141392B2 (en) * | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
FR2821625B1 (fr) * | 2001-03-01 | 2003-05-16 | Genodyssee | Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
WO2002070655A2 (en) | 2001-03-02 | 2002-09-12 | Zymogenetics, Inc. | Mouse cytokine receptor |
AU2002322478A1 (en) * | 2001-03-02 | 2002-12-16 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
KR20090010127A (ko) * | 2001-03-07 | 2009-01-28 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술 |
CN1191271C (zh) * | 2001-03-21 | 2005-03-02 | 中国科学院上海生物化学研究所 | 干扰素-胸腺肽融合蛋白及其制法 |
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
FR2823220B1 (fr) * | 2001-04-04 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo) |
DE60239454D1 (de) | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
US20020193569A1 (en) * | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
WO2002103321A2 (en) * | 2001-06-14 | 2002-12-27 | Anadys Pharmaceuticals, Inc. | Methods of screening for ligands of target molecules |
JP4262594B2 (ja) * | 2001-06-22 | 2009-05-13 | エフ.ホフマン−ラ ロシュ アーゲー | レトロウイルス表面糖タンパク質を含む可溶性複合体 |
US7094757B2 (en) * | 2001-06-22 | 2006-08-22 | Roche Diagnostics Corporation | Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them |
US6962982B2 (en) * | 2001-06-22 | 2005-11-08 | Roche Diagnostics Corporation | Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them |
EP1411880B1 (en) * | 2001-07-11 | 2018-04-25 | University of Miami | Recombinant vsv for the treatment of tumor cells |
US20030104604A1 (en) * | 2001-08-03 | 2003-06-05 | Weiping Yang | Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage |
CN101200503B (zh) * | 2001-08-10 | 2010-07-07 | 中国人民解放军军事医学科学院生物工程研究所 | 血清白蛋白与干扰素的融合蛋白 |
US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US6797493B2 (en) | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
AU2003217612A1 (en) * | 2002-02-21 | 2003-09-09 | Wyeth | GASP1: a follistatin domain containing protein |
JP4429728B2 (ja) * | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | フォリスタチン(follistatin)ドメイン含有タンパク質 |
WO2003076567A2 (en) * | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
US20040063912A1 (en) * | 2002-03-15 | 2004-04-01 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
EA009938B1 (ru) * | 2002-07-17 | 2008-04-28 | Байоджен Айдек Ма Инк. | ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β |
WO2004022097A1 (en) * | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
MXPA05002968A (es) * | 2002-09-16 | 2005-09-08 | Univ Johns Hopkins | Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina. |
KR101388611B1 (ko) | 2002-10-16 | 2014-04-23 | 퍼듀 퍼머 엘피 | 세포-연관된 ca 125/o772p에 결합하는 항체들 및 그것의 용도의 방법들 |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
RU2366664C2 (ru) * | 2002-12-17 | 2009-09-10 | Мерк Патент Гмбх | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 |
MXPA05008704A (es) * | 2003-02-18 | 2005-10-05 | Merck Patent Gmbh | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. |
WO2004091653A1 (en) * | 2003-04-17 | 2004-10-28 | Ares Trading S.A. | Interferon beta in severe acute respiratory syndrome (sars) |
CN1535724B (zh) * | 2003-04-23 | 2012-09-05 | 北京金迪克生物技术研究所 | 重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途 |
AU2004238263A1 (en) * | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Inhibition of drug binding to serum albumin |
EP1624891B2 (en) * | 2003-05-06 | 2013-04-10 | Biogen Idec Hemophilia Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US20070161087A1 (en) * | 2003-05-29 | 2007-07-12 | Wolfgang Glaesner | Glp-1 fusion proteins |
RU2322261C2 (ru) | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
CN1802386B (zh) * | 2003-06-12 | 2010-12-15 | 伊莱利利公司 | Glp-1类似物融合蛋白质 |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
AU2004282984B2 (en) * | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
EP1699822B1 (en) * | 2003-12-30 | 2008-04-23 | MERCK PATENT GmbH | Il-7 fusion proteins with antibody portions, their preparation and their use |
BRPI0417916A (pt) * | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
AU2005206277B2 (en) | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
NZ548256A (en) | 2004-02-02 | 2010-02-26 | Ambrx Inc | Modified human four helical bundle polypeptides and their uses |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
EP1778275A2 (en) * | 2004-08-12 | 2007-05-02 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
WO2006063055A2 (en) * | 2004-12-06 | 2006-06-15 | Bolder Biotechnology, Inc. | Enzyme conjugates for use as detoxifying agents |
BRPI0519000A2 (pt) * | 2004-12-09 | 2008-12-23 | Merck Patent Gmbh | variantes de il-7 com imunogenicidade reduzida |
CA2596390A1 (en) | 2005-02-08 | 2006-08-17 | Zymogenetics, Inc. | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation |
CN101137906A (zh) * | 2005-03-23 | 2008-03-05 | 惠氏公司 | 对gdf-8调节剂的免疫应答的检测 |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
ATE515512T1 (de) | 2005-05-12 | 2011-07-15 | Zymogenetics Inc | Zusammensetzungen und verfahren zur modulierung von immunreaktionen |
CA2609613A1 (en) * | 2005-05-26 | 2006-11-30 | Schering Corporation | Interferon-igg fusion |
MY149128A (en) | 2005-08-16 | 2013-07-15 | Hanmi Science Co Ltd | A method for the mass production of immunoglobulin fc region deleted initial methionine residues |
CA2616479A1 (en) | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
PT1966245E (pt) | 2005-12-30 | 2011-08-31 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
ES2384055T3 (es) * | 2005-12-30 | 2012-06-28 | Merck Patent Gmbh | Variantes de la interleucina-12p40 con estabilidad mejorada |
US7625564B2 (en) * | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
WO2007127936A2 (en) | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
MX2008014971A (es) | 2006-05-24 | 2008-12-05 | Serono Lab | Regimen de cladribine para tratar esclerosis multiple. |
EP2049567A2 (en) * | 2006-07-18 | 2009-04-22 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
EP2292663B1 (en) | 2006-08-28 | 2013-10-02 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic human light-specific human monoclonal antibodies |
EP2407548A1 (en) | 2006-10-16 | 2012-01-18 | MedImmune, LLC | Molecules with reduced half-lives, compositions and uses thereof |
WO2008057529A2 (en) * | 2006-11-06 | 2008-05-15 | Coley Pharmaceutical Group, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp) |
KR100888022B1 (ko) * | 2006-12-21 | 2009-03-09 | 재단법인 목암생명공학연구소 | 면역글로불린 Fc와 인간 아포리포단백질(a)크링글절편의 융합단백질 LK8Fc |
AU2008232902B2 (en) | 2007-03-30 | 2013-10-03 | Medlmmune, Llc | Antibody formulation |
US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
US8067548B2 (en) * | 2007-07-26 | 2011-11-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
AU2008302111B2 (en) * | 2007-09-21 | 2014-04-24 | The Regents Of The University Of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
AU2008308509B2 (en) | 2007-10-04 | 2014-10-23 | Zymogenetics, Inc. | B7 family member zB7H6 and related compositions and methods |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
KR101700711B1 (ko) | 2007-11-21 | 2017-01-31 | 로스킬드 유니베르시테트 | 얼음-결합 활성을 포함하는 폴리펩티드 |
CN101952309A (zh) * | 2007-12-21 | 2011-01-19 | Ifxa有限公司 | 蛋白酶抑制剂 |
WO2009092806A2 (en) * | 2008-01-25 | 2009-07-30 | Aarhus Universitet | Selective exosite inhibition of papp-a activity against igfbp-4 |
CN103694337B (zh) | 2008-02-08 | 2016-03-02 | Ambrx公司 | 经修饰瘦素多肽和其用途 |
WO2010011096A2 (en) | 2008-07-23 | 2010-01-28 | Hanmi Pharmaceutical Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
AU2009274512A1 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of Colorado | Clip inhibitors and methods of modulating immune function |
JP5781501B2 (ja) * | 2009-04-22 | 2015-09-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 改変されたFcRn結合部位を有する抗体融合タンパク質 |
ES2548030T3 (es) | 2009-06-01 | 2015-10-13 | Medimmune, Llc | Moléculas con semividas prolongadas y usos de las mismas |
WO2011020024A2 (en) | 2009-08-13 | 2011-02-17 | The Johns Hopkins University | Methods of modulating immune function |
EA023179B1 (ru) | 2009-08-13 | 2016-05-31 | Круселл Холланд Б.В. | Антитела против респираторного синцитиального вируса (pcb) и способы их применения |
US20110189183A1 (en) | 2009-09-18 | 2011-08-04 | Robert Anthony Williamson | Antibodies against candida, collections thereof and methods of use |
RU2519031C1 (ru) * | 2010-01-19 | 2014-06-10 | Ханми Сайенс Ко., Лтд. | Жидкие препаративные формы для длительно действующего конъюгата g-csf |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
NZ602634A (en) | 2010-03-26 | 2015-06-26 | Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
AR080993A1 (es) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
US20110245469A1 (en) * | 2010-04-02 | 2011-10-06 | Athena Discovery, Inc. | Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives |
EP2558482B1 (en) | 2010-04-16 | 2017-09-27 | Janssen Biotech, Inc. | Engineered plant cysteine proteases and their uses |
UA115120C2 (uk) | 2010-07-09 | 2017-09-25 | Байоджен Хемофіліа Інк. | Спосіб застосування химерного поліпептиду фактора ix |
KR20140002601A (ko) * | 2010-07-09 | 2014-01-08 | 바이오겐 이데크 헤모필리아 인코포레이티드 | 키메라 응고 인자 |
NZ603488A (en) | 2010-07-09 | 2015-02-27 | Crucell Holland Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
CN102585013B (zh) * | 2011-01-07 | 2014-04-23 | 中国人民解放军军事医学科学院生物工程研究所 | 一种含有ω干扰素的融合蛋白及制备方法 |
EP3763740A1 (en) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
CN102212139A (zh) * | 2011-03-29 | 2011-10-12 | 中国人民解放军第二军医大学 | 森林脑炎病毒包膜E蛋白与人抗体Fc段融合蛋白及其用途 |
US9243049B2 (en) * | 2011-08-09 | 2016-01-26 | Uab Profarma | Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof |
KR102323287B1 (ko) | 2011-10-05 | 2021-11-05 | 원드 매터리얼 인코포레이티드 | 리튬 이온 배터리용 실리콘 나노구조체 활물질, 및 그에 관련된 공정, 조성물, 구성요소 및 디바이스 |
CN109022465B (zh) | 2011-10-28 | 2022-04-29 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
EP3290442A1 (en) | 2011-11-04 | 2018-03-07 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs |
KR20150002588A (ko) * | 2012-01-19 | 2015-01-07 | 에스비씨 버락 바이오테크 코., 엘티디. | 인터페론 및 면역글로불린 fc 섹션 융합 단백질 |
TWI492952B (zh) * | 2012-01-20 | 2015-07-21 | Sbc Virbac Ltd | 動物融合重組型干擾素 |
WO2013162050A1 (ja) | 2012-04-23 | 2013-10-31 | 株式会社Nrlファーマ | ラクトフェリン融合タンパク質及びその製造方法 |
CN103044554B (zh) * | 2012-05-14 | 2014-08-27 | 旭华(上海)生物研发中心有限公司 | 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用 |
WO2013177231A1 (en) | 2012-05-21 | 2013-11-28 | Massachusetts Institute Of Technology | Translocation of non-natural chemical entities through anthrax protective antigen pore |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
CN104619722B (zh) * | 2012-06-22 | 2022-10-04 | 达特茅斯大学理事会 | 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途 |
US9334332B2 (en) | 2012-07-25 | 2016-05-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
EP2892558B1 (en) | 2012-09-07 | 2019-04-10 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
WO2014059028A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
WO2014107566A1 (en) | 2013-01-04 | 2014-07-10 | Massachusetts Institute Of Technology | Surface binding of nanoparticle based drug delivery to tissue |
UY35463A (es) | 2013-03-15 | 2014-10-31 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix. |
KR102094022B1 (ko) | 2013-04-29 | 2020-03-30 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-cd38 항체 및 감쇠 인터페론 알파-2b와의 융합체 |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
WO2014194100A1 (en) | 2013-05-29 | 2014-12-04 | The Regents Of The University Of California | Anti-cspg4 fusions with interferon for the treatment of malignancy |
JP6824735B2 (ja) | 2013-06-06 | 2021-02-03 | ピエール、ファーブル、メディカマン | 抗C10orf54抗体およびその使用方法 |
WO2014202089A2 (en) | 2013-06-18 | 2014-12-24 | Roskilde Universitet | Variants of anti-freeze polypeptides |
AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
DK3041507T3 (da) | 2013-08-26 | 2021-07-26 | Biontech Res And Development Inc | Nukleinsyrer, der koder for humane antistoffer mod sialyl-lewis a |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
JP6590810B2 (ja) | 2013-12-24 | 2019-10-16 | ヤンセン ファーマシューティカ エヌブイ | 抗vista抗体および断片 |
SG11201606018UA (en) | 2014-01-24 | 2016-08-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
WO2015161832A1 (zh) * | 2014-04-25 | 2015-10-29 | 辅仁药业集团有限公司 | 长效重组人干扰素α2b-Fc融合蛋白 |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
AU2015259465A1 (en) | 2014-05-13 | 2016-11-17 | Bioatla Llc | Conditionally active biological proteins |
ES2869459T3 (es) | 2014-05-16 | 2021-10-25 | Medimmune Llc | Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas |
KR102226248B1 (ko) | 2014-06-04 | 2021-03-12 | 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 | 강글리오사이드 gd2에 대한 사람 단클론 항체 |
MX2016016310A (es) | 2014-06-11 | 2017-10-20 | A Green Kathy | Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral. |
BR112017004131A2 (pt) | 2014-09-03 | 2017-12-12 | Bioatla Llc | método de produção de uma proteína biológica condicionalmente ativa, proteína biológica condicionalmente ativa, receptor de antígeno quimérico, e, célula citotóxica. |
BR112017008880A2 (pt) | 2014-10-29 | 2018-07-10 | Teva Pharmaceuticals Australia Pty Ltd | variantes de interferon a2b |
CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
MX2017007136A (es) | 2014-12-05 | 2017-12-04 | Immunext Inc | Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8. |
WO2016094837A2 (en) | 2014-12-11 | 2016-06-16 | Igenica Biotherapeutics, Inc. | Anti-c10orf54 antibodies and uses thereof |
ES2937020T3 (es) | 2015-03-03 | 2023-03-23 | Kymab Ltd | Anticuerpos, usos y métodos |
WO2016179518A2 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
JP7026509B2 (ja) | 2015-06-24 | 2022-02-28 | ヤンセン ファーマシューティカ エヌブイ | 抗vista抗体およびフラグメント |
KR20180050679A (ko) | 2015-08-27 | 2018-05-15 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 통증 치료용 조성물 및 방법 |
TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物 |
EP3355920A4 (en) | 2015-09-29 | 2019-05-15 | Celgene Corporation | PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF |
US11472876B2 (en) | 2015-11-02 | 2022-10-18 | Bioatla, Inc. | Conditionally active polypeptides |
TW202216201A (zh) | 2016-02-12 | 2022-05-01 | 比利時商楊森製藥公司 | 抗vista抗體及片段、其用途及鑑定其之方法 |
RU2021111187A (ru) | 2016-04-15 | 2021-04-29 | Янссен Фармасьютикалз, Инк. | Антитела против человеческого vista и их применение |
CN109952317A (zh) | 2016-09-19 | 2019-06-28 | 细胞基因公司 | 使用pd-1结合蛋白治疗免疫病症的方法 |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
CA3080406A1 (en) | 2016-10-28 | 2018-05-03 | Nrl Pharma, Inc. | Lactoferrin/albumin fusion protein and production method thereof |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
EP3694889A1 (en) | 2017-10-13 | 2020-08-19 | Boehringer Ingelheim International GmbH | Human antibodies to thomsen-nouvelle (tn) antigen |
US20230243836A1 (en) | 2018-07-20 | 2023-08-03 | Pierre Fabre Medicament | Receptor for vista |
US20210023236A1 (en) * | 2019-07-26 | 2021-01-28 | Massachusetts Institute Of Technology | Multi-targeted, tunable, sustained delivery of payloads to charged avascular tissues |
JP2024502832A (ja) | 2020-12-31 | 2024-01-23 | アラマー バイオサイエンシーズ, インコーポレイテッド | 高親和性及び/または特異性を有する結合剤分子ならびにその製造及び使用方法 |
EP4047016A1 (en) | 2021-02-19 | 2022-08-24 | Université de Strasbourg | Anti-tenascin-c (tnc) single-domain antibodies (nanobodies) and use thereof |
AR128222A1 (es) | 2022-01-07 | 2024-04-10 | Johnson & Johnson Entpr Innovation Inc | MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b |
WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH648331A5 (de) * | 1979-07-31 | 1985-03-15 | Hoffmann La Roche | Homogenes fibroblasten-interferon und dessen herstellung. |
US4289689A (en) * | 1980-03-14 | 1981-09-15 | Hoffmann-La Roche Inc. | Preparation of homogeneous human fibroblast interferon |
IL58765A (en) * | 1979-11-21 | 1986-09-30 | Yeda Res & Dev | Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta |
NZ198445A (en) * | 1980-09-25 | 1984-05-31 | Genentech Inc | Production of human fibroblast interferon by recombinant dna technology |
JPS57181098A (en) * | 1981-04-30 | 1982-11-08 | Japan Found Cancer | Novel recombinant dna |
JPS58110600A (ja) * | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
SE436275B (sv) * | 1982-11-01 | 1984-11-26 | Malmbom Rune Ingbyra Hb | Anordning vid en utmed ett underlag rorlig lasthanteringsapparat, foretredesvis en lasttruck |
EP0467416A1 (en) * | 1983-09-01 | 1992-01-22 | Hybritech Incorporated | Antibody compositions of therapeutic agents having an extended serum half-life |
EP0173494A3 (en) * | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
DE3523701A1 (de) * | 1985-07-03 | 1987-01-08 | Bayer Ag | Verfahren zur herstellung von proteinen und polypeptiden |
DE3712985A1 (de) * | 1987-04-16 | 1988-11-03 | Hoechst Ag | Bifunktionelle proteine |
CA1339445C (en) * | 1986-11-12 | 1997-09-09 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and method of use |
ES2073394T3 (es) * | 1987-06-10 | 1995-08-16 | Dana Farber Cancer Inst Inc | Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares. |
US4973478A (en) * | 1987-07-20 | 1990-11-27 | Allelix Biopharmaceuticals, Inc. | Treating inflammation with hepatocyte stimulating factor interferon β2 |
SE459586B (sv) * | 1987-09-14 | 1989-07-17 | Mta Szegedi Biolog Koezponti | Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning |
DE3850542T2 (de) * | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
NZ226414A (en) * | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
GB8725529D0 (en) * | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US4978745A (en) * | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
ZA89430B (en) * | 1988-01-22 | 1989-10-25 | Gen Hospital Corp | Cloned genes encoding ig-cd4 fusion proteins and the use thereof |
EP0325224B1 (en) * | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Methods of producing secreted receptor analogs |
EP0355068A3 (en) * | 1988-08-19 | 1991-09-04 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and their use |
CA2010321C (en) * | 1989-02-21 | 2004-04-06 | Thomas F. Tedder | Lymphocyte-associated cell surface protein |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
ATE146968T1 (de) * | 1989-03-16 | 1997-01-15 | Blood Res Center | Verwendung von funkionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie |
WO1991000360A1 (en) * | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
KR927003613A (ko) * | 1989-08-23 | 1992-12-18 | 더 제너랄 호스피탈 코오퍼레이숀 | 비-인체 영장동물의 cd4폴리텝타이드, 글리코실화할 수 있는 인체 cd4분자, 그것의 단편, 그것의 융합 단백질, 유전자 서열 및 그것의 용도 |
DE69034022T2 (de) * | 1989-09-20 | 2003-07-10 | Abbott Laboratories, Abbott Park | Verfahren zur Herstellung von Fusionsproteinen |
AU7766391A (en) * | 1990-04-23 | 1991-11-11 | Corvas International N.V. | Thrombus-specific antibody derivatives |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
-
1996
- 1996-09-25 US US08/719,331 patent/US5723125A/en not_active Expired - Fee Related
- 1996-12-06 MY MYPI96005143A patent/MY116588A/en unknown
- 1996-12-13 JP JP52460997A patent/JP3507507B2/ja not_active Expired - Fee Related
- 1996-12-13 AT AT96945126T patent/ATE355074T1/de not_active IP Right Cessation
- 1996-12-13 CA CA002239522A patent/CA2239522A1/en not_active Abandoned
- 1996-12-13 CN CNB961994223A patent/CN1187086C/zh not_active Expired - Fee Related
- 1996-12-13 AU AU13567/97A patent/AU701579B2/en not_active Ceased
- 1996-12-13 WO PCT/US1996/020861 patent/WO1997024137A1/en active IP Right Grant
- 1996-12-13 DE DE69636938T patent/DE69636938T2/de not_active Expired - Fee Related
- 1996-12-13 EP EP96945126A patent/EP0888122B1/en not_active Expired - Lifetime
- 1996-12-24 ID IDP963910A patent/ID16083A/id unknown
-
1997
- 1997-12-19 US US08/994,719 patent/US5908626A/en not_active Expired - Fee Related
-
1999
- 1999-05-28 HK HK99102391A patent/HK1017261A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE355074T1 (de) | 2006-03-15 |
US5908626A (en) | 1999-06-01 |
EP0888122A4 (en) | 2002-01-09 |
AU701579B2 (en) | 1999-02-04 |
HK1017261A1 (en) | 1999-11-19 |
CN1206350A (zh) | 1999-01-27 |
EP0888122B1 (en) | 2007-02-28 |
MY116588A (en) | 2004-02-28 |
DE69636938T2 (de) | 2007-11-08 |
DE69636938D1 (de) | 2007-04-12 |
JPH11505132A (ja) | 1999-05-18 |
ID16083A (id) | 1997-09-04 |
CA2239522A1 (en) | 1997-07-10 |
US5723125A (en) | 1998-03-03 |
WO1997024137A1 (en) | 1997-07-10 |
AU1356797A (en) | 1997-07-28 |
JP3507507B2 (ja) | 2004-03-15 |
EP0888122A1 (en) | 1999-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1187086C (zh) | 具有经非免疫原性肽连接在一起的干扰素α和免疫球蛋白Fc的杂合体 | |
CN1217956C (zh) | 可溶性单链t细胞受体蛋白 | |
CN100343282C (zh) | 杂合干扰素融合多肽 | |
CN1184235C (zh) | 嵌合多肽、其产生方法及应用 | |
CN1333785A (zh) | 干扰素-β融合蛋白及用途 | |
CN1896103A (zh) | N-端化学修饰的蛋白质组合物及方法 | |
CN1361793A (zh) | 干扰素-α蛋白作为Fc融合蛋白的表达和运输 | |
CN1198929C (zh) | 抗α/β干扰素受体的抗体 | |
CN1723220A (zh) | 含有免疫球蛋白fc区作为载体的药物组合物 | |
CN1076966A (zh) | 抗人白细胞介素-4的人性化单克隆抗体的克隆和表达 | |
CN1090326A (zh) | 白细胞介素-10的哺乳动物受体 | |
CN1194000A (zh) | 增强保护性免疫应答的方法 | |
CN1145693C (zh) | 作为趋化因子拮抗剂的氨基端截短的mcp-2 | |
CN1751122A (zh) | 具有改进特性的干扰素α突变蛋白的融合蛋白 | |
CN1604965A (zh) | 生长激素融合蛋白 | |
CN1282255A (zh) | Ifnar2/1fn复合物 | |
CN1511849A (zh) | 新型α干扰素突变体及其制备方法 | |
CN1245533A (zh) | 哺乳动物趋化因子 | |
CN1113517A (zh) | 转录因子aprf | |
CN87108308A (zh) | 新的多肽及其生产 | |
CN1286976C (zh) | α/β-干扰素结合蛋白,制法及用途 | |
CN1192751A (zh) | 单核细胞趋化蛋白-4 | |
CN1732016A (zh) | 用于癌症治疗的经修饰的细胞因子 | |
CN1220702C (zh) | 促胰岛素分泌肽及其用途 | |
CN1313494C (zh) | 一种具有促增长作用的融合蛋白及其编码基因与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050202 Termination date: 20100113 |